한국임상약학회지 (Korean Journal of Clinical Pharmacy)

  • 제25권2호
  • /
  • Pages.80-93
  • /
  • 2015
  • /
  • 1226-6051(pISSN)
  • /
  • 2508-786X(eISSN)
한국임상약학회 (Korean College Of Clinical Pharmacy)
권호 표지

비호지킨림프종 환자의 발열성 호중구감소증에 대한 페그필그라스팀의 예방효과

Prophylactic Effect of Pegfilgrastim on Febrile Neutropenia in Patients with Non-Hodgikin's Lymphoma

  • 조주희 (숙명여자대학교 임상약학대학원) ;
  • 방준석 (숙명여자대학교 임상약학대학원)
  • Jo, Juhee (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Bang, Joon Seok (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
  • 투고 : 2015.01.30
  • 심사 : 2015.06.08
  • 발행 : 2015.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: Pegfilgrastim is recently introduced that is long acting G-CSF for prophylaxis of febrile neutropenia. Treatment of non-Hodgikin's lymphoma (NHL) with R-CHOP is classified with relative high risk of febrile neutropenia. The study evaluated the prophylactic effect of pegfilgrastim to reduce the incidence of febrile neutropenia associated with R-CHOP of patient in NHL. And the risk factors associated with the incidence of FN and related events were evaluated. Methods: This retrospective study reviews the Electronic Medical Record of 68 NHL patients who received R-CHOP chemotherapy in single center between September 2013 and August 2014. These patients were classified who receive prophylaxis pegfilgrastim or no prophylaxis. Results: Sixty eight patients received R-CHOP with NHL. In 144 cycles of patients receiving pegfilgrastim, compared with no prophylaxis 178 cycles, had a lower incidence of febrile neutropenia (5.5% vs. 23.6%, p = 0.001), grade 3 or grade 4 neutropenia (14.4% vs. 89.8%, p < 0.001) and neutropenia related events (p < 0.05). The risk of febrile neutropenia after prophylaxis was significantly associated with age ${\geq}65$ (OR: 5.87, 95% CI 1.07-32.27, p = 0.042), $IPI{\geq}3$ (OR: 7.2, 95% CI 1.31-39.6, p = 0.023), S.alb < 3.5 g/dL (OR: 31.01, 95% CI 6.32-152.17, p < 0.0001). In multiple logistic regression analysis, lower baseline serum albumin (OR: 21.1, 95% CI 3.8-116.98, p = 0.001) was significantly associated with occurrence of febrile neutropenia. Conclusion: The study recommends prophylactic pegfilgrastim through risk assessment of febrile neutropenia in patients with non-Hodgikin's lymphoma receiving R-CHOP.

키워드

참고문헌

  1. Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther 2003;1(1):23-35. https://doi.org/10.3816/SCT.2003.n.002
  2. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106(10):2258-66. https://doi.org/10.1002/cncr.21847
  3. Bhana N. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review. Curr Opin Oncol 2007;19(4):328-35. https://doi.org/10.1097/01.cco.0000275309.58868.11
  4. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26(2):220-52. https://doi.org/10.3904/kjim.2011.26.2.220
  5. Lyman GH, Kuderer NM. Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 2002;62 Suppl 1:65-78. https://doi.org/10.2165/00003495-200262001-00005
  6. Ministry of Health and Welfare, National cancer center. Annual Report 2011. Available at http://ncc.re.kr/manage/manage03_033_list.jsp (Last accessed Sep 20, 2014).
  7. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84(5):1361-92.
  8. Boyiadzis M, Foon KA. Chapter 100. Diffuse Large B-Cell Lymphoma. In Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT eds. Williams Hematology. 8 ed2010.
  9. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large- B-cell lymphoma. N Engl J Med 2002;346(4):235-42. https://doi.org/10.1056/NEJMoa011795
  10. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9(2):105-16. https://doi.org/10.1016/S1470-2045(08)70002-0
  11. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol 2013;14(6):525-33. https://doi.org/10.1016/S1470-2045(13)70122-0
  12. Lee S, Knox A, Zeng IS, et al. Primary prophylaxis with granulocyte colony-stimulating factor (GCSF) reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma (NHL) receiving CHOP chemotherapy treatment without adversely affecting their quality of life: cost-benefit and quality of life analysis. Support Care Cancer 2013;21(3):841-6. https://doi.org/10.1007/s00520-012-1589-2
  13. Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011;11:404. https://doi.org/10.1186/1471-2407-11-404
  14. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84. https://doi.org/10.1200/JCO.2005.09.102
  15. Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25(21):3158-67. https://doi.org/10.1200/JCO.2006.08.8823
  16. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14(1):29-35. https://doi.org/10.1093/annonc/mdg019
  17. Tan H, Tomic K, Hurley D, et al. Comparative effectiveness of colonystimulating factors for febrile neutropenia: a retrospective study. Curr Med Res Opin 2011;27(1):79-86. https://doi.org/10.1185/03007995.2010.536527
  18. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20(3):727-31. https://doi.org/10.1200/JCO.20.3.727
  19. Naeim A, Henk HJ, Becker L, et al. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013; 13:11. https://doi.org/10.1186/1471-2407-13-11
  20. Weycker D, Malin J, Kim J, et al. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009;31(5):1069-81. https://doi.org/10.1016/j.clinthera.2009.05.019
  21. Product Information. NEULASTA(R) subcutaneous injection, pegfilgrastim subcutaneous injection. Amgen Manufacturing Limited, Thousand Oaks, CA, 2008.
  22. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Myeloid Growth Factors Version 2.2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf (Last accessed Sep 20, 2014).
  23. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidencebased clinical practice guideline. J Clin Oncol 2006;24(19):3187-205. https://doi.org/10.1200/JCO.2006.06.4451
  24. Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. J Natl Compr Canc Netw 2005;3(4):557-71. https://doi.org/10.6004/jnccn.2005.0031
  25. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47(1):8-32. https://doi.org/10.1016/j.ejca.2010.10.013
  26. Health Insurance Review & Assessment Service. Anticancer medications and therapies. Amendment for G-CSF injectable preparations (No. 2006-4). Available at http://www.hira.or.kr/main.do (Last accessed Dec 05, 2014).
  27. Health Insurance Review & Assessment Service. Details about the applicable standards and methods of reimbursement (Notice of HIRA, No. 2013-209). Available at https://m.hira.or.kr/cms/cancerinfo (Last accessed Sep 20, 2014).
  28. Langeberg WJ, Siozon CC, Page JH, et al. Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma. Support Care Cancer 2014;22(8):2167-75. https://doi.org/10.1007/s00520-014-2184-5
  29. Flores IQ, Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clin J Oncol Nurs 2010;14(1):81-6. https://doi.org/10.1188/10.CJON.81-86
  30. Pfeil AM, Allcott K, Pettengell R, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 2014; doi:10.1007/s00520-014-2457-z.
  31. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother 2009;53(10):4069-79. https://doi.org/10.1128/AAC.00341-09
  32. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25(34):5471-89. https://doi.org/10.1200/JCO.2007.12.3851
  33. Perrier L, Lefranc A, Perol D, et al. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy 2013;11(2):129-38. https://doi.org/10.1007/s40258-013-0011-7
  34. Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009;25(2):401-11. https://doi.org/10.1185/03007990802636817
  35. Lathia N, Isogai PK, De Angelis C, et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst 2013;105(15):1078-85. https://doi.org/10.1093/jnci/djt182
  36. Chirivella I, Bermejo B, Insa A, et al. Optimal delivery of anthracycline- based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 2009;114(3):479-84. https://doi.org/10.1007/s10549-008-0018-1
  37. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98(11):2402-9. https://doi.org/10.1002/cncr.11827
  38. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007;12(12): 1416-24. https://doi.org/10.1634/theoncologist.12-12-1416
  39. Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007; 12(4): 484-94. https://doi.org/10.1634/theoncologist.12-4-484
  40. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18(13):2522-8. https://doi.org/10.1200/JCO.2000.18.13.2522
  41. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 2001; 93(1):31-8. https://doi.org/10.1093/jnci/93.1.31
  42. Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005;23(18):4198-214. https://doi.org/10.1200/JCO.2005.05.645
  43. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10(3):181-8. https://doi.org/10.1007/s00520-001-0312-5
  44. Koumakis G, Vassilomanolakis M, Barbounis V, et al. Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide. Oncology 1999;56(1):28-35. https://doi.org/10.1159/000011926
  45. Chan A, Leng XZ, Chiang JY, et al. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia Pac J Clin Oncol 2011;7(1):75-81. https://doi.org/10.1111/j.1743-7563.2010.01355.x
  46. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dosefinding study in women with breast cancer. Ann Oncol 2002;13(6): 903-9. https://doi.org/10.1093/annonc/mdf130
  47. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, openlabel study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21(3):514-9. https://doi.org/10.1200/JCO.2003.03.040
  48. Pettengell R, Schwenkglenks M, Bacon P, et al. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematol Oncol 2011;29(4):177-84. https://doi.org/10.1002/hon.982
  49. Salar A, Haioun C, Rossi FG, et al. The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res 2012;36(5):548-53. https://doi.org/10.1016/j.leukres.2012.02.002
  50. Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy- induced neutropenia. Oncologist 2005;10(6):427-37. https://doi.org/10.1634/theoncologist.10-6-427
  51. Wieringa A, Boslooper K, Hoogendoorn M, et al. Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol 2014;165(4):489-96. https://doi.org/10.1111/bjh.12765
  52. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44(12):2069-76. https://doi.org/10.1080/1042819031000119262
  53. Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009;144(5):677-85. https://doi.org/10.1111/j.1365-2141.2008.07514.x
  54. Chao C, Page JH, Yang SJ, et al. History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis. Ann Oncol 2014; doi:10.1093/annonc/mdu203.
  55. Le AT, Trovato JA. White blood cell growth factor use in an outpatient oncology clinic: Lessons and opportunities learned. J Oncol Pharm Pract 2014;doi:10.1177/1078155214528551.
  56. Waters GE, Corrigan P, Gatesman M, et al. Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic. J Oncol Pract 2013;9(4):203-6. https://doi.org/10.1200/JOP.2012.000662